Results 101 to 110 of about 807 (164)
The Clinical Respiratory JournalABSTRACTBackgroundAzvudine (FNC) is a novel small molecule antiviral drug for treating COVID‐19 that is available only on the Chinese market. Despite being recommended for treating COVID‐19 by the Chinese guidelines, its efficacy and safety are still unclear.
Tao Dong +6 more
openaire +3 more sources
Risk Factors and Nomogram Prediction Model for Healthcare-Associated Infections (HAIs) in COVID-19 Patients [PDF]
Zhanjie Li,1,* Jian Li,2,* Chuanlong Zhu,3 Shengyuan Jiao1,2 1Department of Infection Control, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, People’s Republic of China; 2Department of Disease Prevention ...
Jiao S, Li J, Li Z, Zhu C
core +1 more source
Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study. [PDF]
Front Cell Infect MicrobiolBackgroundAzvudine (AZV), the first Chinese oral anti-coronavirus disease 2019 (COVID-19) drug, has shown substantial clinical benefits to viral clearance and prognosis in patients with mild and common COVID-19. However, there is no evidence in severe hospitalized COVID-19 patients.MethodsIn this multicenter study, we analyzed 209 severe hospitalized ...
Zhang ML +5 more
europepmc +4 more sources
Real-world data-driven early warning system for risk-stratified liver injury in hospitalized COVID-19 patients—Machine learning models for clinical decision support [PDF]
ObjectiveTo develop and validate a real-world evidence-driven early warning system for the risk-stratified prediction of coronavirus disease 2019 (COVID-19)-associated hepatic dysfunction in hospitalized patients, leveraging interpretable machine ...
Feng Lv +9 more
core +1 more source
Severe novel coronavirus infection in late pregnancy: a case report [PDF]
This study reported the diagnosis, treatment and perinatal outcome of a novel coronavirus infection patient at 29+6 weeks pregnancy. The patient case came to the hospital with persistent fever and cough for 6 days.
Liu, Jingjing +3 more
core +2 more sources
Coronavirus Disease 2019 Case Series in China: Sequelae and Effectiveness of Vaccination and Antiviral Drugs [PDF]
Min Ren Department of Emergency, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Min Ren, Department of Emergency, Emergency and Critical Care Medical ...
Ren M
core +1 more source
EClinicalMedicineSummary: Background: Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe infection.
Shuxia Wang +46 more
doaj +1 more source
Acta Pharmaceutica Sinica BThymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homing anti-SARS-CoV-2 drug in treating COVID-19 patients.
Ning Sheng +7 more
openaire +3 more sources